Table 3 Total cell number of untreated and RNase treated cell lines over a certain period of incubation
From: Promises of eukaryotic ribonucleases for cancer treatment: a systematic review
S/N | Author, YYYY | RNase | Experiment | Total cell number* (× 105 cells/ml) | Cell Growth (Proliferation) | ||||
|---|---|---|---|---|---|---|---|---|---|
Cell lines (Description) | Concentration | 0 h | 24 h | 48 h | 72 h | ||||
1 | Ardelt et al., 2007 [24] | Amphinase (Amph) | HL-60 (Human promyelocytic leukemia) U-937 (Human monocytic leukemia) Jurkat cells (T-cell leukemia) | Control | 2.0 | 4.0 | 10.0 | 22.0 | ↓ |
Amph, 1 μg/ml | 2.0 | 4.0 | 5.0 | 7.0 | |||||
Amph, 5 μg/ml | 2.0 | 3.0 | 2.5 | 3.0 | |||||
Amph,10 μg/ml | 2.0 | 2.0 | 2.5 | 2.0 | |||||
2 | Darzynkiewicz et al., 1988 [16] | P-30 protein (Pannon) | HL-60 (Human promyelocytic leukemia) | Control | 2.0 | 4.5 | 8.0 | 17.0 | ↓ |
P-30, 10 μg/ml | 2.0 | 3.0 | 3.5 | 5.5 | |||||
P-30, 20 μg/ml | 2.0 | 2.9 | 2.9 | 2.0 | |||||
3 | Laccetti et al., 1992 [11] | BS-RNase | FRTL-5 (Fischer rat normal thyroid cells) | Control | 0.75 | 5.0 | 10 | 10.5 | ↓↑ |
BS-RNase, 5 µg/ml | 0.75 | 5.0 | 9.5 | 10.3 | |||||
BS-RNase, 10 µg/ml | 0.75 | 4.5 | 9.5 | 10.1 | |||||
BS-RNase, 50 µg/ml | 0.75 | 4.5 | 9.0 | 10.0 | |||||
TK-6 (Fischer rat thyroid tumor cells) | Control | 0.75 | 3.5 | 11.0 | 13.0 | ↓ | |||
BS-RNase, 5 μg/ml | 0.75 | 3.5 | 10.5 | 12.5 | |||||
BS-RNase, 10 μg/ml | 0.75 | 2.5 | 10.0 | 12.0 | |||||
BS-RNase, 50 μg/ml | 0.75 | 2.0 | 8.0 | 10.5 | |||||
MPTK-6 (Fischer rat lung metastasis of TK-6 cells) | Control | 0.75 | 4.0 | 10.5 | 12.5 | ↓ | |||
BS-RNase, 5 μg/ml | 0.75 | 2.5 | 7.5 | 9.0 | |||||
BS-RNase, 10 μg/ml | 0.75 | 2.0 | 5.0 | 8.0 | |||||
BS-RNase, 50 μg/ml | 0.75 | 1.5 | 3.0 | 6.0 | |||||
4 | Castro et al., 2011 [29] | PE5 | NCI/ADR-RES (Drug resistant ovarian cancer cells) | Control | 0.07 | 0.07 | 0.07 | 0.07 | ↓ |
PE5, 2 μM | 0.07 | 0.06 | 0.06 | 0.05 | |||||
PE5, 14 μM | 0.07 | 0.06 | 0.05 | 0.03 | |||||
PE5, 35 μM | 0.07 | 0.06 | 0.04 | 0.01 | |||||
Onconase (Onc®) | NCI/ADR-RES (Drug resistant ovarian cancer cells) | Control | 0.07 | 0.07 | 0.06 | 0.06 | ↓ | ||
Onc, 2 μM | 0.07 | 0.06 | 0.05 | 0.04 | |||||
Onc, 5 μM | 0.07 | 0.06 | 0.05 | 0.04 | |||||